MedTrace Logo

Effectiveness of LNS and MNP Supplements to Prevent Malnutrition in Women and Their Children in Bangladesh

NCT01715038 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4011

Last updated 2017-05-30

No results posted yet for this study

Summary

The program effectiveness study aims to assess the effect of a lipid-based nutrition supplement (LNS) and micronutrient powder (MNP) provided in a programmatic context for improving maternal nutritional status during pregnancy and lactation (LNS only), and preventing malnutrition in infants and young children (LNS and MNP) in Bangladesh.

Conditions

  • Malnutrition

Interventions

DIETARY_SUPPLEMENT

LNS-PLW

Dietary supplement: Lipid-based nutrient supplement Lipid-based nutrient supplement for pregnant and lactating women (LNS-PLW) Daily dose of LNS-PLW will be 20 g, packaged in one sachet

DIETARY_SUPPLEMENT

LNS-Child

Dietary supplement: Lipid-based nutrient supplement Lipid-based nutrient supplement for infants and young children (LNS-Child) Daily dose of LNS-Child will be 20 g, packaged in two 10 g sachets

DIETARY_SUPPLEMENT

MNP

Dietary supplement: Micronutrient powder Micronutrient powder for infants and young children (MNP) The MNP for children will be packaged in 1 g sachets, so that each day, the child will consume one sachet.

DIETARY_SUPPLEMENT

IFA

Dietary supplement: Iron and folic acid nutrient supplement Iron-folic acid tablets for pregnant and lactating women Daily dose of iron-folic acid supplement will be one tablet containing 60 mg iron and 400 mcg folic acid

Sponsors & Collaborators

  • Family Health International 360

    collaborator UNKNOWN

  • International Centre for Diarrhoeal Disease Research, Bangladesh

    collaborator OTHER

  • LAMB Project

    collaborator OTHER

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Kathryn G Dewey, PhD · University of California, Davis

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
49 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2015-06-30
Completion
2015-10-31

Countries

  • Bangladesh

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01715038 on ClinicalTrials.gov